Good news
Recently, Salubris announced that the new drug for diabetes " Fultagliptin benzoate tablet " (Brand name: Xinliting) obtained the drug registration certificate issued by NMPA.
Fultagliptin benzoate tablet (Xinliting) is a dipeptidyl peptidase 4 (DPP-4) inhibitor, which is used to improve blood glucose control in adults with type 2 diabetes (including monotherapy and combination therapy when metformin hydrochloride alone cannot effectively control blood glucose). It is a domestic class 1 innovative drug (project code: SAL067).
Fultagliptin benzoate tablet (Xinliting) inhibited the activity of DPP-4 and decreased the hydrolysis of secret-secreting hormone by DPP-4, further increasing the plasma concentration of the active form of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulin-stimulating polypeptide (GIP), increasing insulin release and decreasing glucagon levels in a glucose-dependent manner, thereby lowering blood glucose. It has the characteristics of rapid oral absorption, lasting effect, high selectivity and good safety.
After the launch of the product, it will provide patients with new treatment options, while further enriching Salubris’ innovative product pipeline and enhancing its comprehensive competitiveness in the field of chronic disease.
| General information of drug registration certificate
· Generic name: Fultagliptin benzoate tablets
· Brand name: Xinliting
· Dosage forms: tablet
· Strengths: 6mg, 12mg
· Registration classification: Chemical 1
· Drug approval number: 国药准字H20240032, H20240033
· Approval date: June 28, 2024
